Mayo Clinic: Carcinoma, Ovarian Epithelial trials

The registry lists 11 Carcinoma, Ovarian Epithelial studies with Mayo Clinic as lead sponsor. 0 are open to participants now and 3 have results posted.

Early Phase 1 4Phase 1 4Phase 2 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent LigandTerminatedNCT01511055Phase 2Results posted
• Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00408590Phase 1Results posted
• Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP InhibitorsCompletedNCT04917744
• Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01747798Early Phase 1
• Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01606241Phase 1
• Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00652691Phase 1